Dezima Pharma is a biopharma company developing novel drugs to treat dyslipidemia.
Dezima Pharma – anti-dyslipidemic compounds
Dyslipidemia is a major modifiable risk for cardiovascular disease. Dezima aims to develop novel anti-dyslipidemic compounds in cardiovascular disease from pre-clinical development to meaningful proof of concept (PoC) in patients. Dezima’s lead program is DEZ-001. DEZ-001 is a potent cholesteryl ester transfer protein (CETP) inhibitor that has shown a significant decrease of low-density lipoprotein (LDL) levels, and an increase of high-density lipoprotein (HDL) levels. DEZ-001 has shown a clean safety profile in clinical single and multiple ascending dose studies with an extensive preclinical and clinical safety and efficacy package supporting further development. Dezima Pharma also recently announced the complete enrolment of a study with TA-8995 in asymptomatic subjects with isolated, severely elevated Lipoprotein(a) (Lp(a)). Following proof of concept, Dezima Pharma will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications.
Dezima Pharma is a biotech company based in Netherlands. Dezima Pharma was founded in 2012 by BioGeneration Ventures and Forbion Capital Partner. Management Team is composed by Rob de Ree, John Kastelein, Patrick Round and John Ford. Board of Directors is composed by Sander Slootweg, Marco Boorsma, Somu Subramaniam and Wil Hazenberg. Scientific Advisory Board is composed by John Kastelein, Philip Barter, Bryan Brewer and Sander van Deventer. Dezima Pharma is continuously scouting for in-licensing opportunities in the dyslipidemia space.
More about Dezima Pharma : www.dezimapharma.com